This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales
William Blair initiates Zentalis (ZNTL) at Outperform, citing a $1.3B peak sales potential for lead cancer drug azenosertib.
Economy · News reference
AstraZeneca, Leidos, Expeditors International And More On CNBC’s ‘Final Trades’
CNBC traders picked AstraZeneca, Leidos, 10-year Treasuries and Expeditors; strong earnings lifted Leidos and Expeditors shares.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Is It Worth Investing in Astrazeneca (AZN) Based on Wall Street's Bullish Views?
While Wall Street analysts maintain a bullish average brokerage recommendation (ABR) of 1.56 for Astrazeneca with 17 Strong Buy ratings, the Zacks Rank system assigns the stock a Strong Sell rating (#5). This contradiction stems from a 10.3% decline in consensus earnings estimates over the past month to $9.16, indicating analyst pessimism about the company's earnings prospects. The article cautions investors against relying solely on brokerage recommendations, which often exhibit positive bias, and suggests the Zacks Rank's focus on earnings estimate revisions is a more reliable predictor of near-term stock performance.
Oligonucleotide Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Sarepta Therapeutics
The global oligonucleotide therapeutics market is projected to grow from USD 7.7 billion in 2025 to USD 72.1 billion by 2035, expanding at a 23.4% CAGR. Growth is driven by advances in RNA-based medicine, targeted delivery technologies, expanding applications beyond rare diseases into chronic and metabolic conditions, and increasing regulatory approvals. Antisense oligonucleotides lead the market at 39.9% share, while subcutaneous administration dominates at 56.4%. North America commands 57.9% market share.
8-K filing — EXPEDITORS INTERNATIONAL OF WASHINGTON INC (EXPD)
Filed: 2026-09-16 AccNo: 0001193125-26-392952 Size: 149 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Joby Aviation Expands Autonomous Flight Reach With Cross-Country Tour
Joby Aviation is conducting a 10-state cross-country tour to demonstrate its J208 autonomous aircraft technology. The aircraft has completed over 400 flights and 800 automated hours while participating in three U.S. military exercises. The tour aims to test diverse environments, strengthen government and industry partnerships, and advance autonomous aviation networks. However, regulatory approvals and broader market acceptance remain key challenges for large-scale commercial adoption.
CNBC Halftime Report Final Trades: AstraZeneca, Leidos Holdings, Expeditors International of Washington, U.S. 10 Year Treasury